Clinical Trial Update: Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial comparing otamixaban versus unfractionated heparin and eptifibatide in non-ST elevation acute coronary syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Non-st-elevation Acute Coronary Syndrome

Drugs mentioned

• EPTIFIBATIDE (EPTIFIBATIDE)
• Otamixaban (otamixaban)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Sanofi | Conditions: Coronary Disease | Phase 2 | Status: COMPLETED